Trump Admin to Crack Down on Misleading Prescription Drug Ads
2025-09-11
This memo outlines the Trump administration's plan to tighten regulations on direct-to-consumer prescription drug advertising. Citing a surge in pharmaceutical advertising and concerns about misleading claims that downplay risks and overemphasize benefits, the administration will mandate more comprehensive risk information in ads to ensure fair, balanced, and complete information for consumers. The goal is to correct misleading information and promote more informed medication choices.